On April 2, 2026, Matinas BioPharma Holdings, Inc. (the 'Company') received a written notice from the NYSE American LLC indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 of the NYSE American Company Guide. The notice states that the Company must maintain stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years. As of December 31, 2025, the Company had stockholders' equity of $4.83 million but has reported losses in the most recent five fiscal years. The Company is required to submit a plan of action to regain compliance by May 2, 2026, and may be eligible for a cure period of up to 18 months. If the plan is accepted, the Company will continue its listing during the cure period, subject to periodic reviews. However, if the plan is not accepted, delisting proceedings will commence. The notice does not immediately impact the trading of the Company's shares, which will continue to be listed on the NYSE American, provided the Company meets other listing requirements. This situation raises concerns about the Company's financial health and its ability to sustain operations in the long term.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.